Chin‐Hee Chung

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Yi‐Long Wu, Shun Lü, You Lü et al. · Journal of Thoracic Oncology · 2018 · 185 citations

Medicine, Oncology, Pharmacology +14

Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]

Francisco Martinez-Torres, Sanjay Menon, Maria Pritsch et al. · BMC Neurology · 2008 · 102 citations · Full text

Pharmacy, Infectious Diseases, Neurology +17

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours

Mohamed Elmeliegy, István Láng, Chin‐Hee Chung et al. · British Journal of Clinical Pharmacology · 2019 · 30 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

A Phase 1 Mass Balance Study of ¹⁴C‐Labeled Talazoparib in Patients With Advanced Solid Tumors

Yanke Yu, Chin‐Hee Chung, Anna Plotka et al. · The Journal of Clinical Pharmacology · 2019 · 21 citations

Medicine, Pharmacokinetics, Pharmacology +14

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i>+ advanced non-squamous non-small cell lung cancer (NSCLC).

Shun Lü, Tony Mok, You Lu et al. · Journal of Clinical Oncology · 2016 · 19 citations

Medicine, Oncology, Pharmacology +10